Biotech firm Rubius raises $120 million | Chemical & Engineering News
Volume 95 Issue 26 | p. 13 | Concentrates
Issue Date: June 26, 2017

Biotech firm Rubius raises $120 million

Department: Business
Keywords: start-ups, oncology, red blood cells, enzyme replacement therapy

Rubius Therapeutics, a Cambridge, Mass.-based developer of red-blood-cell-based therapies, has raised $120 million in a financing round that included its founding investor, Flagship Pioneering, as well as other investors. Rubius engineers red blood cells to express enzymes, agonists, antagonists, and other proteins. Launched in 2014, the company says its lead programs include enzyme replacement therapies and therapies targeting cancer. It expects to start human trials in 2018.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment